CN101443329A - N-(4-氯-3-甲基-5-异唑基)2-[2-甲基-4，5-(亚甲基二氧基)苯乙酰基]噻吩-3-磺酰胺钠盐的多晶型物 - Google Patents

N-(4-氯-3-甲基-5-异唑基)2-[2-甲基-4，5-(亚甲基二氧基)苯乙酰基]噻吩-3-磺酰胺钠盐的多晶型物 Download PDF

Info

Publication number
CN101443329A
CN101443329A CNA2007800174618A CN200780017461A CN101443329A CN 101443329 A CN101443329 A CN 101443329A CN A2007800174618 A CNA2007800174618 A CN A2007800174618A CN 200780017461 A CN200780017461 A CN 200780017461A CN 101443329 A CN101443329 A CN 101443329A
Authority
CN
China
Prior art keywords
methyl
amount
polymorphic form
solvent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800174618A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·F·赖克温
蒂姆·汉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Encysive Pharmaceuticals Inc
Original Assignee
Encysive Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals Inc filed Critical Encysive Pharmaceuticals Inc
Publication of CN101443329A publication Critical patent/CN101443329A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2007800174618A 2006-03-13 2007-03-12 N-(4-氯-3-甲基-5-异唑基)2-[2-甲基-4，5-(亚甲基二氧基)苯乙酰基]噻吩-3-磺酰胺钠盐的多晶型物 Pending CN101443329A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78186106P 2006-03-13 2006-03-13
US60/781,861 2006-03-13

Publications (1)

Publication Number Publication Date
CN101443329A true CN101443329A (zh) 2009-05-27

Family

ID=38335653

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800174618A Pending CN101443329A (zh) 2006-03-13 2007-03-12 N-(4-氯-3-甲基-5-异唑基)2-[2-甲基-4，5-(亚甲基二氧基)苯乙酰基]噻吩-3-磺酰胺钠盐的多晶型物

Country Status (14)

Country Link
US (1) US20090104265A1 (enExample)
EP (1) EP1996582A2 (enExample)
JP (1) JP2009530279A (enExample)
KR (1) KR101019264B1 (enExample)
CN (1) CN101443329A (enExample)
AU (1) AU2007225206B2 (enExample)
BR (1) BRPI0709384A2 (enExample)
CA (1) CA2644134A1 (enExample)
IL (1) IL193682A0 (enExample)
MX (1) MX2008011843A (enExample)
NZ (1) NZ570943A (enExample)
RU (1) RU2412941C2 (enExample)
WO (1) WO2007106467A2 (enExample)
ZA (1) ZA200807302B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112241A1 (en) * 2007-03-13 2008-09-18 Encysive Pharmaceuticals, Inc. Methods an compositions for treatment of an interstitial lung disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5793705A (en) * 1996-09-18 1998-08-11 International Business Machines Corporation Ultrasonic liquid level gauge for tanks subject to movement and vibration
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP4097893B2 (ja) * 2000-12-05 2008-06-11 株式会社エフ・ティ・エスコーポレーション 対向ターゲット式スパッタ方法及び導電性膜の形成方法
ES2274234T3 (es) * 2002-03-15 2007-05-16 Novartis Ag 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3(4-piridin-3-il)pirimidin -2-ilamino)fenil)-benzamida para el tratamiento de enfermedades mediadas por ang ii.
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof

Also Published As

Publication number Publication date
BRPI0709384A2 (pt) 2011-03-22
IL193682A0 (en) 2009-05-04
WO2007106467A3 (en) 2007-10-25
NZ570943A (en) 2010-09-30
MX2008011843A (es) 2008-10-02
CA2644134A1 (en) 2007-09-20
ZA200807302B (en) 2009-11-25
WO2007106467A2 (en) 2007-09-20
AU2007225206A1 (en) 2007-09-20
EP1996582A2 (en) 2008-12-03
KR101019264B1 (ko) 2011-03-07
KR20080106926A (ko) 2008-12-09
AU2007225206B2 (en) 2010-08-05
RU2412941C2 (ru) 2011-02-27
US20090104265A1 (en) 2009-04-23
RU2008136316A (ru) 2010-04-20
JP2009530279A (ja) 2009-08-27

Similar Documents

Publication Publication Date Title
JP2017008081A (ja) 血圧上昇および糖尿病性腎症を処置するための、ビフェニルスルホンアミドエンドセリンおよびアンジオテンシンｉｉ受容体アンタゴニストの経口製剤
WO2002049630A2 (en) Method for preventing or treating pain by administering an endothelin antagonist
US20080076812A1 (en) Formulations of sitaxsentan sodium
MX2009001129A (es) Polimorfos de n-(2-acetil-4,6-dimetilfenil)-3-{[(3,4-dimetil-5-iso xazolil)-amino]sulfonil}-2-tiofeno-carboxamida.
CN101443329A (zh) N-(4-氯-3-甲基-5-异唑基)2-[2-甲基-4，5-(亚甲基二氧基)苯乙酰基]噻吩-3-磺酰胺钠盐的多晶型物
US20080026061A1 (en) Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
HK1127057A (en) Polymorphs of n-(4-chloro-3-methyl-5-isoxazolyl)2-[2-methyl-4,5-(methylenedioxy) phenylacetyl]thiophene-3-sulfonamide, sodium salt
KR20190126291A (ko) 옥사진 유도체를 포함하는 약제학적 조성물 및 알츠하이머병의 치료 또는 예방에 있어서 그의 용도
KR20080104149A (ko) 확장기 심장 부전의 치료를 위한 방법 및 조성물
HK1137172A (en) Polymorphs of n-(2-acetyl-4,6-dimethylphenyl)-3-{[3,4dimethyl-5-isoxazolyl)-amino]sulfonyl}-2-thiophene-carboxamide
US20080317858A1 (en) Formulations of n-(2-acetyl-4,6-dimethylphenyl)-3--2-thiophenecarboxamide
HK1125316A (en) Formulations of sitaxsentan sodium
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1127057

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090527

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1127057

Country of ref document: HK